Absorption and mass balance of piperonyl butoxide following an 8-h dermal exposure in human volunteers.
Dermal absorption, metabolism and excretion of piperonyl butoxide (PBO) was studied using 14C-PBO either by itself as a 3% (w/w) solution in isopropyl alcohol or as a 4% (w/w) solution in an aqueous end-use formulation. Each of these two formulations were tested on four young, healthy male volunteers, using a single topical application on the ventral forearm under non-occlusive conditions for an 8-h period. The application sites were thoroughly cleaned with cotton swabs moistened with isopropyl alcohol, then rinsed with isopropyl alcohol. Blood from the ipsilateral and contralateral arms, urine and feces were collected at selected intervals during the 8-h application and through a 120-h post-application period. The application area was also tape-stripped to determine if any of the test material accumulated in the stratum corneum. These samples provided data which permitted insight into the kinetics of penetration and elimination processes of PBO. The absorption of PBO either by itself or formulated was very poor, as demonstrated by the radioactivity excreted in the urine, and radioactivity in the ipsilateral plasma. When dosed by itself, approximately 1.78% of the dose was excreted in the urine. In contrast, only 0.47% of the formulated PBO was excreted in the urine. Trace radioactivity was detected in the feces from both formulations. The absorbed radioactivity was rapidly eliminated in the urine. There was no evidence of accumulation of PBO in the skin as evidenced by low amounts of radioactivity in the tape-strippings. The majority of the applied radioactivity was recovered from the skin surface. Total recovery of the applied radioactivity was 100.86 and 104.22% for PBO and the formulated product respectively. Absorbed PBO was completely metabolized to at least three major metabolites prior to its excretion in the urine. The three metabolites represented over 70% of the excreted radioactivity for PBO. The HPLC retention times for these metabolites are different than that seen in rats. The structures of these metabolites have not been elucidated.
McLaughlin Gormley King, Minneapolis, MN, USA.
S
S
Selim
F J
FJ
Preiss
K L
KL
Gabriel
J H
JH
Jonkman
T G
TG
Osimitz
D002250:Carbon Radioisotopes; D002851:Chromatography, High Pressure Liquid; D004817:Epidermis / Q000378:metabolism; D006801:Humans; D008297:Male; D010574:Pesticide Synergists / Q000493:pharmacokinetics*; D010882:Piperonyl Butoxide / Q000493:pharmacokinetics*; D012869:Skin Absorption; D013997:Time Factors
D002250:Carbon Radioisotopes; D010574:Pesticide Synergists; D010882:Piperonyl Butoxide